Clinical trial
A 12-Month, Open-Label, Flexible-Dosage Study to Evaluate the Safety of GABITRIL at Dosages up to 16mg/Day in Adults With Generalized Anxiety Disorder
Name
C6671A/301/AX/US
Description
To assess the long-term safety and tolerability of tiagabine treatment in patients with generalized anxiety disorder (GAD).
Trial arms
Trial start
2003-08-01
Estimated PCD
2005-02-01
Phase
Early phase I
Treatment
GABITRIL (tiagabine hydrochloride; CEP-6671)
Size
-1
Eligibility criteria
Not available at time of registration
Protocol
{'studyType': 'INTERVENTIONAL', 'phases': ['PHASE3'], 'designInfo': {'allocation': 'NON_RANDOMIZED', 'interventionModel': 'SINGLE_GROUP', 'primaryPurpose': 'TREATMENT', 'maskingInfo': {'masking': 'NONE'}}}
Updated at
2023-04-12
1 organization
1 product
1 indication
Organization
CephalonProduct
GABITRILIndication
Generalized Anxiety Disorder